280 related articles for article (PubMed ID: 37980492)
1. Altered fecal bile acid composition in active ulcerative colitis.
Sommersberger S; Gunawan S; Elger T; Fererberger T; Loibl J; Huss M; Kandulski A; Krautbauer S; Müller M; Liebisch G; Buechler C; Tews HC
Lipids Health Dis; 2023 Nov; 22(1):199. PubMed ID: 37980492
[TBL] [Abstract][Full Text] [Related]
2. Fecal short chain fatty acids and urinary 3-indoxyl sulfate do not discriminate between patients with Crohn´s disease and ulcerative colitis and are not of diagnostic utility for predicting disease severity.
Tews HC; Elger T; Gunawan S; Fererberger T; Sommersberger S; Loibl J; Huss M; Liebisch G; Müller M; Kandulski A; Buechler C
Lipids Health Dis; 2023 Oct; 22(1):164. PubMed ID: 37789460
[TBL] [Abstract][Full Text] [Related]
3. Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease.
Shimoyama T; Yamamoto T; Yoshiyama S; Nishikawa R; Umegae S
Inflamm Bowel Dis; 2023 Sep; 29(9):1399-1408. PubMed ID: 36334015
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
5. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease.
Mori A; Mitsuyama K; Sakemi R; Yoshioka S; Fukunaga S; Kuwaki K; Yamauchi R; Araki T; Yoshimura T; Yamasaki H; Tsuruta K; Morita T; Yamasaki S; Tsuruta O; Torimura T
Kurume Med J; 2021 Dec; 66(4):209-215. PubMed ID: 34690210
[TBL] [Abstract][Full Text] [Related]
7. New insights into the biological and clinical significance of fecal calprotectin in inflammatory bowel disease.
Amati L; Passeri ME; Selicato F; Mastronardi ML; Penna A; Jirillo E; Covelli V
Immunopharmacol Immunotoxicol; 2006; 28(4):665-81. PubMed ID: 17190742
[TBL] [Abstract][Full Text] [Related]
8. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
[TBL] [Abstract][Full Text] [Related]
9. Pancreatitis-associated protein does not predict disease relapse in inflammatory bowel disease patients.
Nunes T; Etchevers MJ; Sandi MJ; Pinó Donnay S; Grandjean T; Pellisé M; Panés J; Ricart E; Iovanna JL; Dagorn JC; Chamaillard M; Sans M
PLoS One; 2014; 9(1):e84957. PubMed ID: 24416322
[TBL] [Abstract][Full Text] [Related]
10. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
[TBL] [Abstract][Full Text] [Related]
11. Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients.
Lin WC; Wong JM; Tung CC; Lin CP; Chou JW; Wang HY; Shieh MJ; Chang CH; Liu HH; Wei SC;
World J Gastroenterol; 2015 Dec; 21(48):13566-73. PubMed ID: 26730169
[TBL] [Abstract][Full Text] [Related]
12. Patient-Reported Outcomes Correlate With Microbial Community Composition Independent of Mucosal Inflammation in Pediatric Inflammatory Bowel Disease.
Hellmann J; Ta A; Ollberding NJ; Bezold R; Lake K; Jackson K; Dirksing K; Bonkowski E; Haslam DB; Denson LA
Inflamm Bowel Dis; 2023 Feb; 29(2):286-296. PubMed ID: 35972440
[TBL] [Abstract][Full Text] [Related]
13. Role of Calprotectin, IL-6, and CRP in Distinguishing Between Inflammatory Bowel Disease and Diarrhea Predominant Irritable Bowel Syndrome.
Huong BT; Hien NM; Dung NT; Quang DM; Vinh NT; Tu TT; Chi TK; Phuong LB; Nhan NT
Med Arch; 2024; 78(2):105-111. PubMed ID: 38566874
[TBL] [Abstract][Full Text] [Related]
14. High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score.
Bodelier AG; Jonkers D; van den Heuvel T; de Boer E; Hameeteman W; Masclee AA; Pierik MJ
Dig Dis Sci; 2017 Feb; 62(2):465-472. PubMed ID: 27933473
[TBL] [Abstract][Full Text] [Related]
15. Both fecal calprotectin and fecal immunochemical tests are useful in children with inflammatory bowel disease.
Shimizu H; Ebana R; Kudo T; Sato T; Hara T; Hosoi K; Usami M; Yoshida M; Takeuchi I; Nakase H; Iwama I; Arai K; Shimizu T
J Gastroenterol; 2022 May; 57(5):344-356. PubMed ID: 35165800
[TBL] [Abstract][Full Text] [Related]
16. Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease.
Samant H; Desai D; Abraham P; Joshi A; Gupta T; Dherai A; Ashavaid T
Indian J Gastroenterol; 2015 Nov; 34(6):431-5. PubMed ID: 26589229
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children.
Yang Z; Clark N; Park KT
Clin Gastroenterol Hepatol; 2014 Feb; 12(2):253-62.e2. PubMed ID: 23883663
[TBL] [Abstract][Full Text] [Related]
18. Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease.
Hoekman DR; Diederen K; Koot BG; Tabbers MM; Kindermann A; Benninga MA
Eur J Pediatr; 2016 Oct; 175(10):1335-42. PubMed ID: 27573259
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
[TBL] [Abstract][Full Text] [Related]
20. Fecal Matrix Metalloprotease-9 and Lipocalin-2 as Biomarkers in Detecting Endoscopic Activity in Patients With Inflammatory Bowel Diseases.
Buisson A; Vazeille E; Minet-Quinard R; Goutte M; Bouvier D; Goutorbe F; Pereira B; Barnich N; Bommelaer G
J Clin Gastroenterol; 2018 Aug; 52(7):e53-e62. PubMed ID: 28723856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
